Genomic landscape of gastric cancer： molecular classification and potential targets

Gastric cancer imposes a considerable health burden worldwide, and its mortality ranks as the second highest for all types of cancers. The limited knowledge of the molecular mechanisms underlying gastric cancer tumorigenesis hinders the development of therapeutic strategies. However, ongoing collaborative sequencing efforts facilitate molecular classification and unveil the genomic landscape of gastric cancer. Several new drivers and tumorigenic pathways in gastric cancer, including chromatin remodeling genes, RhoA-related pathways, TP53 dysregulation, activation of receptor tyrosine kinases, stem cell pathways and abnormal DNA methylation, have been revealed. These newly identified genomic alterations await translation into clinical di- agnosis and targeted therapies. Considering that loss-of-function mutations are intractable, synthetic lethality could be em- ployed when discussing feasible therapeutic strategies. Although many challenges remain to be tackled, we are optimistic re- garding improvements in the prognosis and treatment of gastric cancer in the near future.